Top Markets
#1 QuantixAI QuantixAI +63.61%
#2 GEKKO GEKKO +43.09%
#3 Versatize Coin Versatize Coin +39.99%
#4 UnifAI Network UnifAI Network +29.42%
#5 MowCat MowCat +29.40%
#6 Storj Storj +29.08%
#7 Pons Pons +28.88%
#8 Prom Prom +28.67%
#9 Kinesis Silver Kinesis Silver +23.94%
#10 Fake World Assets Fake World Assets +22.62%
Coin of the day
QuantixAI QuantixAI
Settings
Language
ENGLISH
Currency
USD
Theme
Vaxart, Inc. Vaxart, Inc.

Vaxart, Inc.

VXRT
Rank in Stocks #20820
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Share Price
$0.50101
Market Cap
$121.27M
Change (1 day)
-3.65%
Change (1 year)
43.15%
Country
US
Trade Vaxart, Inc. (VXRT)

Category

Healthcare
Revenue for Vaxart, Inc. (VXRT)
Revenue in Aug 2026 TTM: 0
According to Vaxart, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Vaxart, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH